AstraZeneca

Company Snapshot

Founded: 1999
Entity Type: Public
Employees: 94,300
Region: The Americas
Revenue: $54,073.0 Millions
Revenue Year: 2024
Segment: Oncology
Headquarter: Cambridge, U.K.
Key Geographics: The Americas, U.K., Rest of Europe, Asia, Africa, Australasia
Corporate Address: 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA, U.K. Tel: +44-(0)20-3749-5000 Web: www.astrazeneca.com

Company Overview

AstraZeneca is a U.K.-based biopharmaceutical company. The company operates in three segments and is focused on our chosen therapy areas: Oncology, Biopharmaceuticals, and rare diseases. The Biopharmaceuticals segment comprises therapeutic areas, including cardiovascular, renal, and metabolism (CVRM), respiratory and immunology (R&I), and vaccines and immune therapies (V&I). The company’s products are sold in over 125 countries.

The company’s R&D focuses on bispecific, inhaled fragments, ADCs, and cell-depleting monoclonal antibodies in antibody therapeutics.

The major brands are Forxiga or Farxiga, Ebymect, Edistride, Xigduo, Bydureon, Lynparza, Bydureon, Xigduo, Edistride, and Ebymect.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

AstraZeneca In Reports

Immunotherapy Drugs: Global Markets

Our Research report provides an overview of the immunotherapy drugs market report analyzes the market trends of immunotherapy drugs with data from 2024, estimates from 2025, projections of compound annual growth rates...

Biological Therapies for Cancer: Technologies and Global Markets

According to our research analyst biological therapies for cancer market includes global revenue ($ Million) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030.

Fusion Proteins: Global Market

Our detailed report on the fusion protein market and analyzes trends It includes global revenue ($ Million) for the base year 2024, estimated data for 2025.

Company's Business Segments

  • Oncology : Cancer Care Africa, the Lung Ambition Alliance
  • Rare Disease : Hypophosphatasia (HPP), Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN), Wilson disease, and Rare cancers.
  • Other Medicines : Cardiovascular (CV), Renal & Metabolism, Respiratory & Immunology, and Vaccines & Immune Therapies.

Applications/End User Industries

  • Oncology
  • Cardiovascular
  • Renal
  • Metabolism
  • Respiratory and Immunology (R&I)
  • Vaccines and Immune Therapies (V&I)
  • Rare Disease
AI Sentiment